Evolent Health Inc. (NYSE:EVH) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the firm. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $27.80.

EVH has been the topic of several recent research reports. FBR & Co boosted their price target on Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a research report on Friday, August 5th. Canaccord Genuity restated a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a research report on Sunday, August 7th. William Blair restated an “outperform” rating on shares of Evolent Health in a research report on Friday, September 30th. Leerink Swann restated a “buy” rating on shares of Evolent Health in a research report on Wednesday, October 5th. Finally, Jefferies Group set a $28.00 price target on Evolent Health and gave the company a “buy” rating in a research report on Tuesday, October 4th.

In other Evolent Health news, major shareholder Board Co Advisory sold 1,936,529 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $22.50, for a total transaction of $43,571,902.50. Following the transaction, the insider now owns 4,445,879 shares in the company, valued at approximately $100,032,277.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Seth Blackley sold 167,672 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total value of $3,611,654.88. Following the transaction, the president now owns 869,848 shares in the company, valued at approximately $18,736,525.92. The disclosure for this sale can be found here. Company insiders own 8.85% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Dowling & Yahnke LLC boosted its position in Evolent Health by 100.0% in the second quarter. Dowling & Yahnke LLC now owns 40,000 shares of the company’s stock valued at $768,000 after buying an additional 20,000 shares during the last quarter. American Century Companies Inc. boosted its position in Evolent Health by 50.3% in the second quarter. American Century Companies Inc. now owns 282,982 shares of the company’s stock valued at $5,433,000 after buying an additional 94,751 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Evolent Health by 14.2% in the second quarter. Bank of New York Mellon Corp now owns 341,806 shares of the company’s stock valued at $6,563,000 after buying an additional 42,414 shares during the last quarter. California State Teachers Retirement System boosted its position in Evolent Health by 14.0% in the second quarter. California State Teachers Retirement System now owns 31,915 shares of the company’s stock valued at $613,000 after buying an additional 3,912 shares during the last quarter. Finally, Swiss National Bank boosted its position in Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares during the last quarter. Institutional investors own 37.14% of the company’s stock.

Evolent Health (NYSE:EVH) opened at 21.05 on Wednesday. The stock’s market cap is $1.43 billion. Evolent Health has a 52-week low of $8.14 and a 52-week high of $26.84. The stock has a 50 day moving average price of $21.18 and a 200 day moving average price of $20.78.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The firm had revenue of $60.20 million for the quarter, compared to analysts’ expectations of $58.35 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) EPS. On average, equities research analysts forecast that Evolent Health will post ($0.57) EPS for the current year.

WARNING: “Analysts Set Evolent Health Inc. (EVH) Price Target at $27.80” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/26/analysts-set-evolent-health-inc-evh-price-target-at-27-80.html.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.